Jonathan M. Ahmann

446 total citations
13 papers, 224 citations indexed

About

Jonathan M. Ahmann is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Jonathan M. Ahmann has authored 13 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Hematology and 3 papers in Genetics. Recurrent topics in Jonathan M. Ahmann's work include Ubiquitin and proteasome pathways (3 papers), Multiple Myeloma Research and Treatments (3 papers) and Acute Myeloid Leukemia Research (2 papers). Jonathan M. Ahmann is often cited by papers focused on Ubiquitin and proteasome pathways (3 papers), Multiple Myeloma Research and Treatments (3 papers) and Acute Myeloid Leukemia Research (2 papers). Jonathan M. Ahmann collaborates with scholars based in United States, Germany and United Kingdom. Jonathan M. Ahmann's co-authors include Laura A. Bruins, A. Keith Stewart, Esteban Braggio, Chang-Xin Shi, Xuewei Wang, Patrick Jedlowski, K. Martin Kortüm, Yuan Xiao Zhu, Moulun Luo and Yuan Xiao Zhu and has published in prestigious journals such as Blood, Cancer Research and Genome Research.

In The Last Decade

Jonathan M. Ahmann

11 papers receiving 219 citations

Peers

Jonathan M. Ahmann
Jonathan M. Ahmann
Citations per year, relative to Jonathan M. Ahmann Jonathan M. Ahmann (= 1×) peers Jean‐Valère Malfuson

Countries citing papers authored by Jonathan M. Ahmann

Since Specialization
Citations

This map shows the geographic impact of Jonathan M. Ahmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan M. Ahmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan M. Ahmann more than expected).

Fields of papers citing papers by Jonathan M. Ahmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan M. Ahmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan M. Ahmann. The network helps show where Jonathan M. Ahmann may publish in the future.

Co-authorship network of co-authors of Jonathan M. Ahmann

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan M. Ahmann. A scholar is included among the top collaborators of Jonathan M. Ahmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan M. Ahmann. Jonathan M. Ahmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Zhao, Helong, Kent C. Johnson, Anthony D. Pomicter, et al.. (2025). The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia. Haematologica. 111(1). 135–148.
2.
高橋, 義行, Xiaomeng Huang, Philip J. Moos, et al.. (2024). A Bayesian framework to study tumor subclone–specific expression by combining bulk DNA and single-cell RNA sequencing data. Genome Research. 34(1). 94–105. 2 indexed citations
3.
Zhao, Helong, Kent C. Johnson, Anthony D. Pomicter, et al.. (2023). AML-302 Targeting Small GTPase ARF6 Suppresses AML and Spares Host's Normal Physiology. Clinical Lymphoma Myeloma & Leukemia. 23. S287–S288. 1 indexed citations
4.
Zhu, Yuan Xiao, Chang-Xin Shi, Laura A. Bruins, et al.. (2019). Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer Journal. 9(2). 19–19. 70 indexed citations
5.
Patel, Ami B., Emilie Leroy, Soo Jin Kim, et al.. (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood. 134(26). 2388–2398. 21 indexed citations
6.
Pomicter, Anthony D., Dongqing Yan, Jamshid S. Khorashad, et al.. (2019). The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Advances. 3(20). 2949–2961. 27 indexed citations
7.
Yan, Dongqing, Anthony D. Pomicter, William L. Heaton, et al.. (2018). SIRT5 As a Therapeutic Target in Acute Myeloid Leukemia. Blood. 132(Supplement 1). 907–907. 1 indexed citations
8.
Shi, Chang-Xin, K. Martin Kortüm, Yuan Xiao Zhu, et al.. (2017). CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma. Molecular Cancer Therapeutics. 16(12). 2862–2870. 42 indexed citations
9.
Zhu, Yuan Xiao, Chang-Xin Shi, Laura A. Bruins, et al.. (2017). Loss of FAM46C Promotes Cell Survival in Myeloma. Cancer Research. 77(16). 4317–4327. 53 indexed citations
10.
Eiring, Anna M., Jonathan M. Ahmann, Clinton C. Mason, et al.. (2017). Loss of G0S2 in Kinase-Independent TKI Resistance and Blastic Transformation of CML. Blood. 130. 4173–4173. 1 indexed citations
11.
Zhu, Yuan Xiao, Patrick Jedlowski, K. Martin Kortüm, et al.. (2015). Identification of FAM46C As a Multiple Myeloma Repressor. Blood. 126(23). 836–836. 2 indexed citations
12.
Shi, Chang‐Xin, K. Martin Kortüm, Yuan Xiao Zhu, et al.. (2015). Crispr Sgrnas Genome-Wide Screen Identifies the Proteasome Regulatory Subunit PSMC6 As a Bortezomib Resistance Gene in Human Multiple Myeloma Cells. Blood. 126(23). 450–450. 3 indexed citations
13.
Ahmann, Jonathan M.. (2001). Therapeutic Cloning and Stem Cell Therapy. The National Catholic Bioethics Quarterly. 1(2). 145–150. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026